Outset Medical Inc

Outset Medical Inc(OM)股票分析

$3.640

-0.171 (-4.71%)收盤時

Loading chart…
High
3.720
Open
3.710
VWAP
3.66
Vol
134.03K
Mkt Cap
214.13M
Low
3.628
Amount
490.90K
EV/EBITDA, TTM
-2.16

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.

AI analysis of Outset Medical Inc (OM)

sell

Outset Medical Inc is not a good buy right now due to its current price of $3.94, which is significantly below analyst targets of $10 and $6, indicating potential upside. However, the stock has a very low RSI of 24.845, suggesting it is oversold, but the high debt to equity ratio of 101.94% poses a significant risk.

估值指標

The current forward P/E ratio for Outset Medical Inc (OM) is 0.00, compared to its 5-year average forward P/E of -6.50.

Forward P/E

Overvalued
5Y Average P/E
-6.50
Current P/E
0.00
高估
-0.84
低估
-12.16

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-5.36
Current EV/EBITDA
-2.16
高估
-0.35
低估
-10.38

Forward P/S

Fair
5Y Average P/S
5.09
Current P/S
0.53
高估
10.84
低估
-0.67

Alphio AI Price Scenarios for OM

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OM

$19.05

情境價格

B

Base

Base · 50%OM

$18.74

情境價格

B

Bear

Bear · 25%OM

$14.07

情境價格

Whales holding OM

K

Konwave AG (Gold 2000)

+ HoldingOM

+4.28%

3M Return

G

Glencore plc

+ HoldingOM

-17.46%

3M Return

事件時間軸

2026-05-07 (ET)

16:50:00

Company Reports Q1 Revenue of $27.86M, Below Expectations

16:50:00

Outset Reiterates 2026 Revenue Guidance of $125M to $130M

2026-02-11 (ET)

16:10:00

Outset Provides 2026 Revenue Guidance of $125M to $130M

16:10:00

Outset Medical Reports Q4 Revenue of $28.87M

2026-01-27 (ET)

09:10:00

Outset Medical Receives FDA 510(k) Clearance

資訊

OM FAQ — answered by Alphio AI

Outset Medical, Inc. is a medical technology company. It offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. It designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. Tablo comprises various components, including Tablo Console, Tablo Cartridge, and Tablo Data Ecosystem. The Tablo Console is a proprietary, compact, and mobile machine consisting of an integrated water purification, on-demand dialysate production system and simple-to-use touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Outset Medical Inc is not a good buy right now due to its current price of $3.94, which is significantly below analyst targets of $10 and $6, indicating potential upside. However, the stock has a very low RSI of 24.845, suggesting it is oversold, but the high debt to equity ratio of 101.94% poses a significant risk.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始